Business

Cellceutix enters into a collaborative agreement with Beth Israel Deaconess

Cellceutix Corp., a Beverly biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, said it plans to collaborate with Beth Israel Deaconess Medical Center on a research project that will explore the potential of a Cellceutix drug candidate for treating certain types of cancer.

According to Cellceutix, Beth Israel wants to look into the the nuclear and mitochondrial pro-apoptotic function of p53 in melanoma and renal cell carcinoma, two types of cancer that are particularly resistant to therapy.

Advertisement

The p53 signaling pathway is a crucial regulator of cell cycle and apoptosis.

On its website, Cellceutix says that its drug candidate Kevetrin has “demonstrated the potential for a major breakthrough in cancer research by exhibiting an activation of p53.”

Get Talking Points in your inbox:
An afternoon recap of the day’s most important business news, delivered weekdays.
Thank you for signing up! Sign up for more newsletters here

The collaborative studies are independent from the planned clinical trials for Kevetrin, Cellceutix said in a press release.

In a statement, Cellceutix chief executive Leo Ehrlich said: “Beth Israel Deaconess Medical Center will be researching Kevetrin for indications in addition to those which we will be studying in our company-sponsored clinical trials. If they collect promising data in their research of Kevetrin in melanoma and renal cell carcinoma, additional grant and government funding may become available to further study these separate indications, saving us substantial time and money towards the end goal of commercialization.”

Chris Reidy can be reached at reidy@globe.com.
Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com